Guggenheim Starts Kythera Biopharmaceuticals (KYTH) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts KYTH Hot Sheet
Price: $74.98 --0%
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 13 | New: 42
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 13 | New: 42
Join SI Premium – FREE
Guggenheim initiated coverage on Kythera Biopharmaceuticals (NASDAQ: KYTH) with a Buy rating and a price target of $64.00.
For an analyst ratings summary and ratings history on Kythera Biopharmaceuticals click here. For more ratings news on Kythera Biopharmaceuticals click here.
Shares of Kythera Biopharmaceuticals closed at $52.57 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Starts Figure Technology (FIGR) at Buy
- RBC Capital Starts DHL Group (DHL:GR) at Outperform
- Stephens Assumes ACI Worldwide (ACIW) at Equal Weight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
